British Journal of Anaesthesia, 2000, Vol. 85, No. 4 520-528
© 2000 The Board of Management and Trustees of the British Journal of Anaesthesia
Peripheral lidocaine but not ketamine inhibits capsaicin-induced hyperalgesia in humans
1Department of Neurology, University Hospital of Aarhus, DK-8000 Aarhus and Danish Pain Research Center, Aarhus University, Aarhus, Denmark. 2Department of Neurology, University Hospital of Aarhus, DK-8000 Aarhus, Denmark. 3Center for Sensory–Motor Interaction, Aalborg University, Denmark
We examined the effect of the subcutaneous infiltration of ketamine, lidocaine and saline before injury on capsaicin-induced pain and hyperalgesia. Twelve healthy volunteers participated in two separate, randomized, double-blind, placebo-controlled crossover experiments. In experiment 1, 100 µg capsaicin was injected intradermally in one volar forearm 10 min after the skin had been pretreated with lidocaine 20.0 mg in 2.0 ml or 0.9% saline 2.0 ml at the capsaicin injection site. In experiment 2, a similar capsaicin test was given 10 min after the skin had been pretreated with ketamine 5 mg in 2.0 ml or 0.9% saline 2.0 ml. To control for possible systemic effects, the capsaicin injection site was pretreated by injection of saline into the skin and the contralateral arm was treated with active drug, and vice versa. Outcome measures were spontaneous pain, pain evoked by punctate and brush stimuli, and areas of brush-evoked and punctate-evoked hyperalgesia. Lidocaine reduced all measures compared with placebo (P<0.001), whereas ketamine failed to change any measures. Pain scores and areas of hyperalgesia were not affected when the contralateral site was infiltrated with ketamine or lidocaine. Lidocaine produced no side-effects, whereas ketamine produced paraesthesia, dizziness and sleepiness in six out of 24 (25%) cases. Blocking peripheral sodium channels with locally administered lidocaine reduces spontaneous pain and capsaicin-induced hyperalgesia but local block with the NMDA-type glutamate receptor antagonist ketamine has no effect on capsaicin-induced pain and hyperalgesia.
Br J Anaesth 2000; 85: 520–8.
* Corresponding author: Danish Pain Research Center, Building 1C, Aarhus Kommunehospital, DK-8000 Aarhus C, Denmark
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  B. L. Whitsel, O. V. Favorov, Y. Li, M. Quibrera, and M. Tommerdahl Area 3a Neuron Response to Skin Nociceptor Afferent Drive Cereb Cortex, June 4, 2008; (2008) bhn086v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. A. Chizh Low dose ketamine: a therapeutic and research tool to explore N-methyl-D-aspartate (NMDA) receptor-mediated plasticity in pain pathways J Psychopharmacol, May 1, 2007; 21(3): 259 - 271. [Abstract] [PDF]
|
|
|
|
 |
|
 A. Tarral, P. Dostert, Y. Guillevic, L. Fabbri, I. Rondelli, F. Mariotti, and B. P. Imbimbo Safety, Pharmacokinetics, and Pharmacodynamics of CHF 3381, a Novel N-Methyl-D-Aspartate Antagonist, after Single Oral Doses in Healthy Subjects J. Clin. Pharmacol., August 1, 2003; 43(8): 901 - 911. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Sawynok Topical and Peripherally Acting Analgesics Pharmacol. Rev., March 1, 2003; 55(1): 1 - 20. [Abstract] [Full Text] [PDF]
|
|